Benitec Biopharma (BNTC) vs Evommune (EVMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Evommune (EVMN) over the past year, losing 40.3% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $285.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | EVMN |
|---|---|---|
| Share price | $7.92 | $7.04 |
| Market cap | $285.88M | $291.10M |
| 1-day change | -2.76% | -2.76% |
| YTD return | -41.24% | -58.88% |
| 1-year return | -40.31% | -62.37% |
| 5-year return | -85.67% | — |
| EPS (TTM) | $-1.02 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.00M |
| Revenue growth (YoY) | — | +85.71% |
| Net income (latest FY) | $-45.55M | $-68.87M |
| Operating margin | — | -623.62% |
| Net margin | — | -529.77% |
| 52-week high | $14.39 | $33.20 |
| 52-week low | $7.72 | $4.94 |
| Distance from 52-week high | -45.00% | -78.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +200.06% | +210.94% |
| Average volume | 174.01K | 841.65K |
| Shares outstanding | 36.12M | 41.35M |
| Employees | 24 | 48 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNTC has outperformed EVMN by 22.1 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
BNTC vs EVMN FAQ
Which is bigger, Benitec Biopharma or Evommune?
Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $285.88M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, BNTC or EVMN?
BNTC returned -40.31% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Evommune in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.